Ser66

Site Information
LALTRsssLSDFSWs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4767694

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 )
Disease tissue studied:	brain cancer ( 5 ) , glioblastoma ( 5 ) , glioma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 3 ) , acute myelogenous leukemia ( 3 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , KG-1 (myeloid) ( 3 ) , leukocyte-blood ( 4 ) , M059K (glial) ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
3	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
4	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
5	Stokes M (2005) CST Curation Set: 912; Year: 2005; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info